Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells
Iranian Journal of Pharmaceutical Research · 21.05.2022 · 21 (1)
DOI: 10.5812/ijpr-127352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 21.05.2022. Verfasst von Mohsen Soltanshahi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
: Tumor-targeted therapy with small-molecule inhibitors (SMIs) has been demonstrated to be a highly effective therapeutic strategy for various cancers. However, their possible associations with immune evasion mechanisms remain unknown. This study examined the association of inhibitors of the protein kinase B (AKT), mammalian target of rapamycin (mTOR), and Bruton’s tyrosine kinase (BTK) signaling pathways with the expression of immune checkpoint ligands programmed death-ligand 1 (PD-L1), CD155, and galectin-9 (Gal-9) in a breast cancer cell line. MCF-7 cells were treated with everolimus, MK-2206, and ibrutinib. An MTT assay was used to determine the optimal dose for all drugs. A real-time polymerase chain reaction was utilized to measure the mRNA expression of PD-L1, CD155, and Gal-9. The western blot technique was also employed to evaluate the protein expression of the phosphorylated signal transducer and activator of transcription 3 (STAT3). The optimal doses of everolimus, MK-2206, and ibrutinib were observed to be 200, 320, and 2000 nM, respectively. The PD-L1 and CD155 mRNA expression was significantly decreased following the treatment with everolimus and ibrutinib, but not with MK-2206. There were no differences in Gal-9 expression between the single-treated and control groups; however, combined treatment with everolimus and ibrutinib increased its mRNA expression. Everolimus and ibrutinib both inhibited constitutive STAT3 phosphorylation in MCF-7, which was more pronounced in combination treatment. The findings regarding the modulation of PD-L1, CD155, and Gal-9 molecules by SMIs emphasize the crosstalk between the expression of these immune checkpoint molecules and AKT/mTOR/BTK signaling pathways through STAT3 as a critical transcription factor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
- Gastrointestinal Cancer Research Center, Noncommunicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Zitieren
APA
Soltanshahi, M., Taghiloo, S., & Asgarian-Omran, H. (2022). Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells. Iranian Journal of Pharmaceutical Research, 21(1). https://doi.org/10.5812/ijpr-127352
Vancouver
Soltanshahi M, Taghiloo S, Asgarian-Omran H. Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells. Iranian Journal of Pharmaceutical Research. 2022;21(1). doi:10.5812/ijpr-127352
BibTeX
@article{Soltanshahi2022,
author = {Soltanshahi, Mohsen and Taghiloo, Saeid and Asgarian-Omran, Hossein},
title = {Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2022},
volume = {21},
number = {1},
doi = {10.5812/ijpr-127352}
}
EUVIMED